Provided by Tiger Trade Technology Pte. Ltd.

GeneDx Holdings

78.90
-1.8000-2.23%
Post-market: 79.200.3000+0.38%17:18 EST
Volume:591.47K
Turnover:47.06M
Market Cap:2.31B
PE:-108.08
High:82.38
Open:81.16
Low:78.39
Close:80.70
52wk High:170.87
52wk Low:55.17
Shares:29.29M
Float Shares:19.94M
Volume Ratio:0.65
T/O Rate:2.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7300
EPS(LYR):-0.7339
ROE:-7.60%
ROA:-1.55%
PB:7.50
PE(LYR):-107.50

Loading ...

BRIEF-Time Names Genedx CEO Katherine Stueland To The 2026 Time100 Health List Of The World’S Most Influential Leaders In Health

Reuters
·
Feb 11

Time Names GeneDx CEO Katherine Stueland to the 2026 Time100 Health List of the World’s Most Influential Leaders in Health

THOMSON REUTERS
·
Feb 11

Wells Fargo Upgrades GeneDx Holdings to Overweight From Equalweight

MT Newswires Live
·
Feb 09

GeneDx Holdings Corp. : Wells Fargo Raises to Overweight From Equal Weight

THOMSON REUTERS
·
Feb 09

U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup

Reuters
·
Feb 09

GeneDx COO Bryan Dechairo Reports Disposal of Common Shares

Reuters
·
Feb 07

GeneDx Holdings Corp. to Release Fourth Quarter Financial Results

Reuters
·
Feb 03

Analysts Are Bullish on Top Healthcare Stocks: Immutep Ltd (PRRUF), GeneDx Holdings (WGS)

TIPRANKS
·
Feb 02

Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx today

TIPRANKS
·
Jan 31

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

GlobeNewswire
·
Jan 27

GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives

Simply Wall St.
·
Jan 16

Health Minister Responds to Reports of Two Super Flu Cases in Bali

Tempo
·
Jan 15

Stock Track | GeneDx Holdings Plummets 5.07% Intraday Amid Mixed Analyst Opinions

Stock Track
·
Jan 13

GeneDx Shares Down 2.5% After Announcing Preliminary Q4 Results, 2026 Outlook

THOMSON REUTERS
·
Jan 12

GeneDx Reports Preliminary Q4 Revenue; Issues 2026 Revenue Guidance

MT Newswires Live
·
Jan 12

Genedx Holdings Corp. unveils presentation highlighting advances in rare disease diagnosis and genomics-driven healthcare

Reuters
·
Jan 12

GeneDx reports preliminary Q4 revenue $121M, consensus $120.49M

TIPRANKS
·
Jan 12

GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth

Reuters
·
Jan 12

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

THOMSON REUTERS
·
Jan 12

GeneDx Holdings Corp - Expects 2025 Revenues of $427 Mln

THOMSON REUTERS
·
Jan 12